John Blankenhorn

John Blankenhorn

InvestorPlace Contributor

Expertise: Biochemistry, biotechnology and pharmaceutical research

John Blankenhorn has been a researcher since 2016 and has years of experience and publications on the topics of biochemistry, biotechnology, and pharmaceutical research. His main interests are the application of biology and biotechnology to our daily lives, as well as the use of Machine Learning and AI to speed up research and development in the life sciences. He currently works at Emory University studying the structural basis of Alzheimer’s Disease.

Recent Articles

3 Dividend Stocks to Sell Before They Get Disrupted by Technology

By John Blankenhorn, InvestorPlace Contributor

Dividend stocks can be a value trap that needs to be avoided. As technology disrupts their industries, here's 3 dividend stocks to sell. XRX, ARLP, BXP

3 Stocks to Bet on for the Future of Supersonic Travel

By John Blankenhorn, InvestorPlace Contributor

Lockheed Martin, Kratos, and Raytheon are all in the race to help build the first supersonic passenger jet since the Concorde.

3 Medical Device Stocks to Buy for Cutting-Edge Innovation and Growth

By John Blankenhorn, InvestorPlace Contributor

Medical device stocks are set to rise with an aging population and continued improvements in technology. Here are 3 stocks to watch.

3 Quantum Computing Stocks That Are Leading the Race

By John Blankenhorn, InvestorPlace Contributor

Quantum computing may upend modern encryption and bring a new dawn of computing power. Here are 3 quantum computing stocks to watch out for.

3 Carbon Capture Stocks Actually Capturing Carbon

By John Blankenhorn, InvestorPlace Contributor

Many companies talk about capturing carbon, here are three carbon capture stocks that actually do it. Fuel Cell Energy, Fluor and NRG Energy.

Load More